$0.29
7.57% yesterday
Nasdaq, Sep 27, 10:18 pm CET
ISIN
US90138Q1085
Symbol
ME
Sector
Industry

23andMe Holding Co - Ordinary Shares - Class A Stock price

$0.29
-0.03 8.89% 1M
-0.22 42.38% 6M
-0.62 67.81% YTD
-0.69 70.14% 1Y
-8.43 96.63% 3Y
-9.51 97.00% 5Y
-9.51 97.00% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.02 7.57%
ISIN
US90138Q1085
Symbol
ME
Sector
Industry

Key metrics

Market capitalization $161.01m
Enterprise Value $63.70m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.32
P/S ratio (TTM) P/S ratio 0.81
P/B ratio (TTM) P/B ratio 1.12
Revenue growth (TTM) Revenue growth -32.67%
Revenue (TTM) Revenue $199.19m
EBIT (operating result TTM) EBIT $-288.27m
Free Cash Flow (TTM) Free Cash Flow $-139.31m
Cash position $171.47m
EPS (TTM) EPS $-1.31
P/E forward negative
P/S forward 0.97
EV/Sales forward 0.38
Short interest 6.51%
Show more

Is 23andMe Holding Co - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

23andMe Holding Co - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:

Buy
50%
Hold
50%

Financial data from 23andMe Holding Co - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
199 199
33% 33%
100%
- Direct Costs 137 137
28% 28%
69%
62 62
41% 41%
31%
- Selling and Administrative Expenses 143 143
21% 21%
72%
- Research and Development Expense 181 181
21% 21%
91%
-261 -261
14% 14%
-131%
- Depreciation and Amortization 27 27
23% 23%
14%
EBIT (Operating Income) EBIT -288 -288
15% 15%
-145%
Net Profit -631 -631
93% 93%
-317%

In millions USD.

Don't miss a Thing! We will send you all news about 23andMe Holding Co - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

23andMe Holding Co - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
3 days ago
Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics
Neutral
GlobeNewsWire
3 days ago
PHILADELPHIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ: ME) regarding the mass resignation of all of the independent members of the board of directors following the presentation of an offer by the CEO and co-founder, Anne Wojcicki, to acquire the remaining shares of the company not currently owned by her or her affil...
Neutral
GlobeNewsWire
4 days ago
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos & Bacine is investigating 23andMe Holding Co. (NASDAQ: ME) regarding the mass resignation of all of the independent members of the board of directors following the presentation of an offer by the CEO and co-founder, Anne Wojcicki, to acquire the remaining shares of the company not currently owned by her or her affil...
More 23andMe Holding Co - Ordinary Shares - Class A News

Company Profile

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Head office United States
CEO Anne Wojcicki
Employees 582
Founded 2006
Website www.23andme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today